Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10805	Companies
233874	Keywords
162571	Articles
124910	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 03/11/2026 at 08:00, 4 months 25 days ago

BIOPHYTIS ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT
Biophytis completes over €2.0 million capital increase and repays all variable price convertible debt, attracting investments from U.S. healthcare institutions and strengthening financial structure for clinical development in sarcopenia and obesity

Biophytis Healthcare Institutions Capital Increase Clinical Development Convertible Debt
BRIEF

published on 02/27/2026 at 23:05, 5 months 6 days ago

Biophytis Expands Bond Facility with Hexagon Capital to €2 Million

Biophytis Clinical Development Financial Strategy Hexagon Capital Bond Facility
REGULATED PRESS RELEASE

published on 02/27/2026 at 23:00, 5 months 6 days ago

Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
Biophytis increases its bond facility ceiling to €2 million with Hexagon Capital Fund, extending subscription period and strengthening financial structure

Biophytis Financial Structure Subscription Period Hexagon Capital Fund Bond Facility
PRESS RELEASE

published on 02/27/2026 at 22:59, 5 months 6 days ago

Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
Biophytis increases bond facility to €2 million with Hexagon Capital Fund, extending subscription period. CEO and Director comment on the partnership

Biophytis Clinical Development Finance Hexagon Capital Fund Bond Facility
BRIEF

published on 01/28/2026 at 07:35, 6 months 8 days ago

Biophytis Secures $20 Million for Sarcopenia Phase 3 Trial in Asia

Biophytis Joint Venture Phase 3 Trial Sarcopenia Asian Markets
REGULATED PRESS RELEASE

published on 01/28/2026 at 07:30, 6 months 8 days ago

Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Biophytis announces strategic agreement in Asia and secures $20 million for Phase 3 trial in sarcopenia, including creation of joint venture in Hong Kong and financing over 3 years

Biophytis Joint Venture Phase 3 Trial Sarcopenia Strategic Agreement
BRIEF

published on 01/12/2026 at 09:05, 6 months 24 days ago

Biophytis to Engage in Major Healthcare and Investment Events

Biophytis BIOMED Forum Longevity Therapies Healthcare Investment JP Morgan Healthcare
REGULATED PRESS RELEASE

published on 01/12/2026 at 09:00, 6 months 24 days ago

Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Biophytis announces participation in JP Morgan Healthcare Conference and Biomed Forum in January 2026, presenting latest operational and clinical progress

Biophytis BIOMED Forum Age-related Diseases JP Morgan Healthcare Conference Transformative Therapies
PRESS RELEASE

published on 01/12/2026 at 08:59, 6 months 24 days ago

Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Biophytis to participate in JP Morgan Healthcare Conference and Biomed Forum to engage with global financial and pharmaceutical communities for 2026 outlook

Biophytis BIOMED Forum Healthcare Conference JP Morgan 2026
BRIEF

published on 11/13/2025 at 18:35, 8 months 22 days ago

Results of Biophytis' General Meeting Held on November 13, 2025

Financial Statements Biophytis Shareholder Approval General Meeting Thérapies

Accesswire

Published on 08/06/2026 at 03:35, 2 hours 15 minutes ago

Tunkillia Upgrade Drilling – 39,000m Phase 2 Complete Targeting JORC Resource Classification Upgrades; PFS Underway
Published on 08/06/2026 at 01:40, 4 hours 10 minutes ago

Taranis Identifies a Hydrothermally Altered, Sulfide-Bearing Intrusive Stock Associated with Historic Gold-Silver Occurrence and Connected to Thor
Published on 08/05/2026 at 23:40, 6 hours 10 minutes ago

Galantas Gold Secures Key Permitting Approvals for Andacollo Gold Project
Published on 08/05/2026 at 23:10, 6 hours 40 minutes ago

Ur-Energy Announces Date for Second Quarter 2026 Results and Conference Call and Webcast
Published on 08/05/2026 at 23:01, 6 hours 49 minutes ago

Full Circle Lithium Announces Extension of Current Private Placement

View all ACCESSWIRE

EQS Group

Published on 08/05/2026 at 23:23, 6 hours 27 minutes ago

EQS-Adhoc: Enapter AG: Agreement with Patrimonium to discharge corporate bond liabilities of around EUR 26 million; realignment to an asset-light business model; capital measure planned
Published on 08/05/2026 at 23:04, 6 hours 46 minutes ago

AUTODOC to publish H1 2026 report and host a conference call on Q2 results on 13 August 2026
Published on 08/05/2026 at 19:14, 10 hours 36 minutes ago

2CRSi informs the market about the governance of AETHER Infrastructures and the progress of the AETHER project in which 2CRSi takes part as a member of the consortium
Published on 08/05/2026 at 18:45, 11 hours 5 minutes ago

Holding(s) in Company
Published on 08/05/2026 at 18:30, 11 hours 20 minutes ago

Avolta enters Kolkata Airport, growing duty-free presence in India

Les Echos

Published on 08/05/2026 at 18:00, 11 hours 50 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of July 31, 2026
Published on 08/05/2026 at 17:49, 12 hours ago

Mersen: Number of shares and voting rights as of July 31, 2026
Published on 08/05/2026 at 17:45, 12 hours 5 minutes ago

Information concerning the total number of voting rights and shares 2026 07 31
Published on 08/05/2026 at 17:45, 12 hours 5 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/05/2026 at 17:42, 12 hours 8 minutes ago

Aéroports de Paris SA - Shares and voting rights as of 31 July 2026

View all LES ECHOS COMFI WIRE